BACKGROUND: The prognostic benefits of beta-blockers (BB) in patients with systolic heart failure (SHF) are known but despite this, in patients with diabetes they are underutilized. The aim of this study was to assess the effect of beta-blockers (BB) on glycaemic control in patients with Type 2 Diabetes (T2DM) and systolic heart failure (SHF) stratified to beta-1 selective (Bisoprolol) vs. nonselective BB (Carvedilol). METHODS: This observational, cohort study was conducted in patients with T2DM and SHF attending an Australian tertiary teaching hospital's heart failure services. The primary endpoint was glycaemic control measured by glycosylated haemoglobin (HbA1c) at initiation and top dose of BB. Secondary endpoints included microalbuminu...
Background/Aims Beta-blockers (BBs) have been shown to improve clinical outcomes in heart failure (H...
Background: Patients with type 2 diabetes mellitus (T2DM) are at high risk of heart failure. A summa...
Background: In patients with heart failure, beta-blochade has improved morbidity and left-ventricula...
Abstract Background The prognostic benefits of beta-blockers (BB) in patients with systolic heart fa...
BACKGROUND: Diabetes is frequently associated with heart failure and is an independent risk factor f...
BACKGROUND: The effects of beta-blocker therapy in patients with type 2 diabetes (T2D) and establish...
Background: Beta-blockers are often prescribed to patients with heart failure (HF) without distincti...
BACKGROUND There has been no head to head comparison of the clinical outcomes between bisoprolol an...
OBJECTIVE: Diabetes increases mortality in patients with chronic heart failure (CHF) and reduced lef...
Beta-blockers are underutilised in heart failure because clinicians may be unsure whether all beta-b...
BACKGROUND: In patients with heart failure, beta-blockade has improved morbidity and left-ventricula...
The beneficial effects of beta blockers in younger patients with heart failure (HF) due to systolic ...
β-Blockers (BBs) are an essential class of cardiovascular medications for reducing morbidity and mor...
Information on the effectiveness of beta-blockade in patients with heart failure (HF) and concomitan...
Background Beta-blockers (BBs) are the mainstay prognostic medication for all stages of chronic hear...
Background/Aims Beta-blockers (BBs) have been shown to improve clinical outcomes in heart failure (H...
Background: Patients with type 2 diabetes mellitus (T2DM) are at high risk of heart failure. A summa...
Background: In patients with heart failure, beta-blochade has improved morbidity and left-ventricula...
Abstract Background The prognostic benefits of beta-blockers (BB) in patients with systolic heart fa...
BACKGROUND: Diabetes is frequently associated with heart failure and is an independent risk factor f...
BACKGROUND: The effects of beta-blocker therapy in patients with type 2 diabetes (T2D) and establish...
Background: Beta-blockers are often prescribed to patients with heart failure (HF) without distincti...
BACKGROUND There has been no head to head comparison of the clinical outcomes between bisoprolol an...
OBJECTIVE: Diabetes increases mortality in patients with chronic heart failure (CHF) and reduced lef...
Beta-blockers are underutilised in heart failure because clinicians may be unsure whether all beta-b...
BACKGROUND: In patients with heart failure, beta-blockade has improved morbidity and left-ventricula...
The beneficial effects of beta blockers in younger patients with heart failure (HF) due to systolic ...
β-Blockers (BBs) are an essential class of cardiovascular medications for reducing morbidity and mor...
Information on the effectiveness of beta-blockade in patients with heart failure (HF) and concomitan...
Background Beta-blockers (BBs) are the mainstay prognostic medication for all stages of chronic hear...
Background/Aims Beta-blockers (BBs) have been shown to improve clinical outcomes in heart failure (H...
Background: Patients with type 2 diabetes mellitus (T2DM) are at high risk of heart failure. A summa...
Background: In patients with heart failure, beta-blochade has improved morbidity and left-ventricula...